Cefipime: Difference between revisions
Annhuang04 (talk | contribs) |
Annhuang04 (talk | contribs) |
||
| Line 34: | Line 34: | ||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: | *Pregnancy: Category B (no evidence of risk in humans) | ||
*Lactation: | *Lactation: very small amount excreted, adverse effects unlikely, infant should be monitored closely | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
***febrile neutropenia | |||
**** GFR 30-60: 2g q12h | |||
**** GFR 11-29: 2g q24h | |||
**** GFR < 11: 2g x1, then 1g q24h | |||
**** HD: 1g q24, give after dialysis | |||
**** PD: 2g q24h | |||
***all other infections | |||
**** GFR 30-60: q24h dosing | |||
**** GFR 11-29: give usual dose x1, then 0.5-1g q24 | |||
**** GFR < 11: give usual dose x1, then 250-500mg q24h | |||
**** HD: 1g x1, then 500mg q24h, give after dialysis | |||
**** PD: usual dose q48h | |||
**Pediatric | **Pediatric | ||
***febrile neutropenia, cystic fibrosis | |||
****GFR 30-60: 50mg/kg q12h | |||
****GFR 11-29: 50mg/kg q24h | |||
****GFR < 11: 50mg/kg x1, then 25mg/kg q24 | |||
****HD: 25mg/kg q24, give after dialysis | |||
****PD: 50mg/kg q48 | |||
***all other infections | |||
****GFR 30-60: 50mg/kg q24 | |||
****GFR 11-29: 50mg/kg x1, then 25-50mg/kg q24 | |||
****GFR < 11: 50mg/kg x1, then 12.5-25mg/kg q24h | |||
****HD: 50mg/kg x1, then 25mg/kg q24h, give after dialysis | |||
****PD: 50mg/kg q48h | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: no adjustment | ||
**Pediatric | **Pediatric: no adjustment | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 00:52, 3 September 2015
General
- Type: cephalosporin (4th generation)
- Dosage Forms: IM/IV
- Common Trade Names: Maxipime
Adult Dosing
- 1-2 g IV q12h
febrile neutropenia
- 2g IV q8h
UTI, mild-mod
- 0.5g - 1g q12h x 7-10days
UTI, severe
- 2g IV q12h x 10days
Pediatric Dosing
infection, bacterial
>2 months
50mg/kg IV/IM q12hr, max 2g/dose
febrile neutropenia
>2 months
50mg/kg IV/IM q8h; max 2g/dose
resp. infection, cystic fibrosis pts
> 2 months
50mg/kg IV/IM q8h; max 2g/dose
Special Populations
- Pregnancy: Category B (no evidence of risk in humans)
- Lactation: very small amount excreted, adverse effects unlikely, infant should be monitored closely
- Renal Dosing
- Adult
- febrile neutropenia
- GFR 30-60: 2g q12h
- GFR 11-29: 2g q24h
- GFR < 11: 2g x1, then 1g q24h
- HD: 1g q24, give after dialysis
- PD: 2g q24h
- all other infections
- GFR 30-60: q24h dosing
- GFR 11-29: give usual dose x1, then 0.5-1g q24
- GFR < 11: give usual dose x1, then 250-500mg q24h
- HD: 1g x1, then 500mg q24h, give after dialysis
- PD: usual dose q48h
- febrile neutropenia
- Pediatric
- febrile neutropenia, cystic fibrosis
- GFR 30-60: 50mg/kg q12h
- GFR 11-29: 50mg/kg q24h
- GFR < 11: 50mg/kg x1, then 25mg/kg q24
- HD: 25mg/kg q24, give after dialysis
- PD: 50mg/kg q48
- all other infections
- GFR 30-60: 50mg/kg q24
- GFR 11-29: 50mg/kg x1, then 25-50mg/kg q24
- GFR < 11: 50mg/kg x1, then 12.5-25mg/kg q24h
- HD: 50mg/kg x1, then 25mg/kg q24h, give after dialysis
- PD: 50mg/kg q48h
- febrile neutropenia, cystic fibrosis
- Adult
- Hepatic Dosing
- Adult: no adjustment
- Pediatric: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
